The Medical Faculty of the University of Istanbul, Turkey has successfully administered intravenous human immunoglobulin, which is used in the treatment of some COVID-19 patients in intensive care.
Patients undergoing treatment have a lower risk of death than other patients, Qadin.Net reports citing publika.az.
In this group of patients, the estimated mortality rate of more than 60% fell to 40%.
Figen Esen, the head of the resuscitation department at Istanbul Medical Faculty Hospital, began writing a scientific article after the results of the treatment of coronavirus, a generic name for IVIG, used in the treatment of immunodeficiency and some other autoimmune diseases.
This method will be the basis for conducting more advanced clinical research in the world.
Following this success of Istanbul University, Phase-3 research has been launched at various centers in the United States to evaluate the efficacy and safety of IVIG in coronavirus patients.